New research suggests that GLP-1 weight loss medications may provide major long-term benefits for heart health in addition to helping people lose weight and manage blood sugar.
Researchers at Anglia Ruskin University (ARU) reviewed data from more than 90,000 participants involved in large international clinical trials. Their analysis found that people taking glucagon-like peptide-1 (GLP-1) receptor agonists had a significantly lower risk of serious cardiovascular problems compared with those who received a placebo.
The findings were published in Cardiovascular Diabetology -- Endocrinology Reports.
Long-Term Heart Protection Confirmed
The researchers examined results from 11 major cardiovascular outcome trials that followed patients for at least one year. On average, participants were monitored for nearly three years.
